(Reuters) -OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other ...

Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.

MIAMI and JERUSALEM - OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) have announced a collaboration to develop an oral treatment for obesity and other metabolic disorders.

OPKO Health (OPK) and Entera Bio (ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a ...

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...

OPKO and Entera Bio collaborate to develop an oral dual agonist for obesity and metabolic disorders, aiming for FDA application soon. OPKO Health, Inc. and Entera Bio Ltd. have announced a ...

Entera Bio (NASDAQ:ENTX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a ...